Jasper scraps pivotal plans but adds a new indication as more biotechs revise pipelines
A suite of biopharmas disclosed cuts to their pipelines this week as the industry gets a sweeping update of drugs in the works as part of the annual JP Morgan Healthcare Conference.
Jasper Therapeutics, Acticor Biotech, NGM Bio and Annexon were among those to slash parts of their development plans.
The moves follow a rough 2022 for the market, in which dozens of biotechs shifted priorities to conserve cash and stay afloat. Biopharmas routinely fine-tune their pipelines, but the consistency of culls and layoffs last year stood out.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.